Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Lung Cancer

Lucanix Vaccine Therapy for NSCLC (UW08006)
Phase III Lucanix™ Vaccine Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Following Front-Line Chemotherapy (STOP)
Status Conditions Phase Study ID
Closed Lung Neoplasm
Carcinoma, Non-Small-Cell Lung: Stage IIIA (T3,N2 Only)
Carcinoma, Non-Small-Cell Lung: Stage IIIB
Carcinoma, Non-Small-Cell Lung: Stage IV
Phase III UW08006, 20062200
NCT00676507
Summary

Rationale: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than a placebo as maintenance therapy in treatment of subjects with non-small cell lung cancer.

Purpose: This randomized phase III trial is studying vaccine therapy to see how well it works compared with a placebo in treating subjects with stage III or stage IV non-small cell lung cancer.


Investigator
Keith Eaton, MD, PhD
Location    
Seattle Cancer Care Alliance 800-804-8824 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)
Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with histologically or cytologically confirmed NSCLC who meet one of the following staging requirements:
  • Stage IIIA (T3N2 only) or
  • Stage IIIB or
  • Stage IV.
  • Subjects must have stable disease (SD) or an objective response (PR or CR) to a prior single, frontline, platinum-based chemotherapy regimen (additional prior adjuvant chemotherapy is permitted) consisting of up to six (6) treatment cycles with or without concomitant radiation therapy.
  • Not less than one month nor more than four months must have elapsed since the completion of the last chemotherapy cycle and registration into the study.
  • Signed informed consent.
  • Not less than 18 years and not more than 75 years old.
  • Estimated life expectancy of at least 12 weeks.
  • Performance status (ECOG) ≤ 2.
  • Absolute neutrophil count ≥ 1,500/mm3.
  • Hemoglobin ≥ 9 g/dL.
  • Platelet count ≥ 100,000/mm3.
  • Albumin levels ≥ 3.5 g/dL.
  • Bilirubin ≤ 1.5 times the upper limit of normal (ULN).
  • Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 1.5 × ULN.
  • Creatinine ≤ 1.5 × ULN.
  • Alkaline phosphatase ≤ 5 × ULN.

Exclusion Criteria:

  • Concurrent systemic steroids > 2 mg /day prednisone (or prednisone-equivalent of prednisolone or dexamethasone).
  • Prior splenectomy.
  • Any surgery involving general anesthesia < 4 weeks prior to study registration.
  • Chemotherapy more than 4 months or less than 4 weeks prior to study registration.
  • Steroid therapy (excluding ≤ 2 mg/day prednisone or prednisone-equivalent of prednisolone or dexamethasone), radiation therapy, or immunotherapy less than 4 weeks prior to study registration.
  • Objective evidence of brain metastases.
  • Painful bone metastases, or bone metastases that require immediate therapy.
  • Significant and/or symptomatic pleural effusions. Presence of clinically detectable (by physical exam) third-space fluid collections, for example, pleural effusions that cannot be controlled by previous chemotherapy and/or drainage, or other procedures, prior to study entry.
  • Known allergies to eggs or soy.
  • Significant weight loss (≥ 10% body weight in preceding 6 weeks).
  • Known HIV positivity (EBV origin of replication in the pCHEK/HBA2 vector used to modify the vaccine components can trans-activate HIV).
  • Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections) or other conditions that, in the opinion of the investigator, would compromise study objectives.
  • NCI CTC Grade 3 or 4 peripheral neuropathy at study registration.
  • Prior other malignancies (excluding non-melanoma carcinomas of the skin) unless in remission for ≥ 2 years.
  • History of psychiatric disorder that would impede ability to give informed consent or adherence to study requirements.
  • Pregnant or nursing women, or refusal to practice contraception if of reproductive potential.
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Known active Epstein-Barr infection within ≤ 60 days of study registration.
Last Updated
November 15, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.